Secarna Pharmaceuticals and Orbit Discovery enter collaboration to discover and develop peptide-conjugated targeted antisense oligonucleotide therapeutics
- Partnership expands spectrum of Secarna's capabilities for the development of targeted ASOs beyond antibodies and sugar molecules
- New platform capabilities extend the reach of Secarna's antisense approaches, potentially offering new treatment options for a wider range of diseases